



EFW

DOCKET NO.: C1039.70083US00


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Krieg et al.
Serial No.: 10/690,495
Confirmation No.: 8657
Filed: October 21, 2003
For: IMMUNOMODULATORY OLIGONUCLEOTIDES

Examiner: Nina Archie
Art Unit: 1645

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 5th day of February, 2007.



Jamieson K. Herrick

MAIL STOP AMENDMENT

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Transmitted herewith are the following documents:

- Information Disclosure Statement
- PTO Form 1449 with cited references
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.


A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By: 

Helen C. Lockhart, Ph.D., Reg. No.: 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: C1039.70083US00
Date: February 5, 2007
xNDDx



DOCKET NO.: C1039.70083US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Krieg et al.
Serial No.: 10/690,495
Confirmation No.: 8657
Filed: October 21, 2003
For: IMMUNOMODULATORY OLIGONUCLEOTIDES
Examiner: Nina Archie
Art Unit: 1645

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 5th day of February, 2007.



Jamieson K. Herrick

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office action on the merits in the above-identified case.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following co-pending applications that may contain subject matter related to this application:

<u>Serial No.</u>	<u>Filing Date</u>	<u>Inventor(s)</u>	<u>Docket No.</u>
11/503,377	08-11-2006	Krieg et al.	*C1039.70061US01
11/507,079	08-18-2006	Krieg et al.	*C1039.70035US04
11/526,197	09-22-2006	Krieg et al.	*C1039.70048US23
11/526,896	09-22-2006	Bratzler et al.	*C1037.70013US03
11/542,845	10-04-2006	Krieg et al.	*C1037.70048US01
11/543,314	10-04-2006	Lipford et al.	*C1041.70036US02
11/595,823	11-10-2006	Wagner et al.	*C1041.70035US01
11/598,207	11-10-2006	Krieg et al.	*C1039.70048US24
11/603,978	11-22-2006	Forsbach et al.	*C1041.70053US02
11/629,106	12-08-2006	Lipford et al.	*C1041.70027US01
11/645,106	12-22-2006	Krieg et al.	*C1039.70083US17

*A copy of this reference is not provided as the Office has waived the requirement under 37 C.F.R. 1.98(a)(2)(iii) for submitting a copy of a cited U.S. patent application if it is scanned to the Image File Wrapper system and is available on Private PAIR.

The Applicant would like to bring to the Examiner's attention the following other information, whose relevance is discussed in Part III below:

PART III: Explanation of Non-English Language References and Remarks Concerning Other Information Cited

The following are remarks concerning the other information cited:

The instant patent application derives priority from US 6,194,388 B1, which is a priority application for US 6,207,646 B1, which was involved in Interference No. 105171. In view of the priority, Applicants have included on the attached 1449 a listing of all of the motions filed, the judgment rendered by the Board of Patent Appeals and Interferences, appeal briefs, and appeal decision, which considered the 35 U.S.C. §135(b)(1) motion dispositive. Copies of these documents are enclosed for the Examiner's review. If the Examiner would like any additional information on this subject, she is encouraged to contact Applicant's representative at the number listed below.

PART IV: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Serial No.: 10/690,495
Conf. No.: 8657

- 4 -


Art Unit: 1645

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.


Respectfully submitted,

By:



Helen C. Lockhart, Ph.D., Reg. No. 39,248
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: C1039.70083US00
Date: February 5, 2007
xNDDx



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.: 10/690,495	ATTY. DOCKET NO.: C1039.70083US00
FILING DATE: October 21, 2003	CONFIRMATION NO.: 8657
APPLICANT: Krieg et al.	
GROUP ART UNIT: 1645	EXAMINER: Nina Archie

Sheet

1

of

20

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		4,452,775		Kent	06-05-1984
		4,981,684		MacKenzie et al.	01-01-1991
		5,075,109		Tice et al.	12-24-1991
		5,178,860		MacKenzie et al.	01-12-1993
		5,543,152		Webb et al.	08-06-1996
		5,595,756		Bally et al.	01-21-1997
		5,679,354		Morein et al.	10-21-1997
		5,705,385		Bally et al.	01-06-1998
		5,736,152		Dunn	04-07-1998
		5,753,613		Ansell et al.	05-19-1998
		5,766,920		Babbitt et al.	06-16-1998
		5,785,992		Ansell et al.	07-28-1998
		5,814,335		Webb et al.	09-29-1998
		5,965,542		Wasan et al.	10-12-1999
		5,968,909		Agrawal et al.	10-19-1999
		5,976,567		Wheeler et al.	11-02-1999
		5,981,501		Wheeler et al.	11-09-1999
		6,027,726		Ansell	02-22-2000
		6,027,732		Morein et al.	02-22-2000
		6,030,955		Stein et al.	02-29-2000
		6,090,791		Sato et al.	07-18-2000
		6,110,745		Zhang et al.	08-29-2000
		6,121,434		Peyman et al.	09-19-2000
		6,207,819	B1	Manoharan et al.	03-27-2001
		6,348,312		Peyman et al.	02-19-2002
		6,476,000	B1	Agrawal et al.	11-05-2002
		6,544,518	B1	Friede et al.	04-08-2003
		6,558,670	B1	Friede et al.	05-06-2003
		6,605,708		Habus et al.	08-12-2003
		6,610,308		Haensler	08-26-2003
		6,610,661	B1	Carson et al.	08-26-2003
		6,630,455	B1	Mitchell	10-07-2003

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/690,495		ATTY. DOCKET NO.: C1039.70083US00	
				FILING DATE: October 21, 2003		CONFIRMATION NO.: 8657	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie	
Sheet	2	of	20				

		6,815,429	B2	Agrawal	11-09-2004
		6,849,725	B2	Junghans et al.	02-01-2005
		7,001,890		Wagner et al.	02-26-2006
		7,105,495	B2	Agrawal et al.	09-12-2006
		7,129,222	B2	Van Nest et al.	10-31-2006
		2001-0036462	A1	Fong et al.	11-01-2001
		2002-0009457	A1	Bowersock et al.	01-24-2002
		2002-0055477	A1	Van Nest et al.	05-09-2002
		2002-0065236	A1	Yew et al.	05-30-2002
		2002-0137714	A1	Kandamilla et al.	09-26-2002
		2002-0192184	A1	Carpentier et al.	12-19-2002
		2003-0022852	A1	Van Nest et al.	01-30-2003
		2003-0059773	A1	Van Nest et al.	03-27-2003
		2003-0086900	A1	Low et al.	05-08-2003
		2003-0104044	A1	Semple et al.	06-05-2003
6		2003-0109469	A1	Carson et al.	06-12-2003
		2003-0119774	A1	Foldvari et al.	06-26-2003
		2003-0125279	A1	Junghans et al.	07-03-2003
		2003-0129251	A1	Van Nest et al.	07-10-2003
		2003-0165478	A1	Sokoll et al.	09-04-2003
		2003-0186921	A1	Carson et al.	10-02-2003
		2003-0203861	A1	Carson et al.	10-30-2003
		2003-0232780	A1	Carson et al.	12-18-2003
		2004-0006010	A1	Carson et al.	01-08-2004
		2004-0006034	A1	Raz et al.	01-08-2004
		2004-0013688	A1	Wise et al.	01-22-2004
		2004-0047869	A1	Garcon et al.	03-11-2004
		2004-0058883	A1	Phillips et al.	03-25-2004
		2004-0092468	A1	Schwartz et al.	05-13-2004
		2004-0097719	A1	Agrawal et al.	05-20-2004
		2004-0132677	A1	Fearon et al.	07-08-2004
		2004-0136948	A1	Fearon et al.	07-15-2004
		2004-0248837	A1	Raz et al.	12-09-2004
		2005-0004144	A1	Carson et al.	01-06-2005
		2005-0031638	A1	Dalemans et al.	02-10-2005
		2005-0064401	A1	Olek et al.	03-24-2005

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/690,495		ATTY. DOCKET NO.: C1039.70083US00	
				FILING DATE: October 21, 2003		CONFIRMATION NO.: 8657	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie	
Sheet	3	of	20				

		2005-0079152	A1	Bot et al.	04-14-2005
		2005-0130918	A1	Agrawal et al.	06-16-2005
		2005-0176672	A1	Scheule et al.	08-11-2005
		2005-0181035	A1	Dow et al.	08-18-2005
		2005-0191342	A1	Tam et al.	09-01-2005
		2005-0209184	A1	Klinman et al.	09-22-2005
		2005-0214355		Klinman et al.	09-29-2005
		2005-0249794	A1	Semple et al.	11-10-2005
		2005-0266015	A1	Clerici et al.	12-01-2005
		2005-0277604	A1	Krieg et al.	12-15-2005
		2005-0277609	A1	Krieg et al.	12-15-2005
		2006-0003955	A1	Krieg et al.	01-05-2006
		2006-0003962	A1	Ahluwalia et al.	01-05-2006
		2006-0014713	A1	Agrawal et al.	01-19-2006
		2006-0019909	A1	Agrawal et al.	01-26-2006
		2006-0019916	A1	Krieg et al.	01-26-2006
		2006-0019923	A1	Davis et al.	01-26-2006
		2006-0058251	A1	Krieg et al.	03-16-2006
		2006-0074040	A1	Kandimalla et al.	04-06-2006
		2006-0089326	A1	Krieg et al.	04-27-2006
		2006-0094683	A1	Krieg et al.	05-04-2006
		2006-0140875	A1	Krieg et al.	06-29-2006
		2006-0154890	A1	Bratzler et al.	07-13-2006
		2006-0172966	A1	Lipford et al.	08-03-2006
		2006-0188913	A1	Krieg et al.	08-24-2006
		2006-0189550	A1	Jiang et al.	08-24-2006
		2006-0211639	A1	Bratzler et al.	09-21-2006
		2006-0211641	A1	Agrawal et al.	09-21-2006
		2006-0211644	A1	Krieg et al.	09-21-2006
		2006-0223769	A1	Dow et al.	10-05-2006
		2006-0229271	A1	Krieg et al.	10-12-2006
		2006-0241076	A1	Uhlmann et al.	10-26-2006
		2006-0246035	A1	Ahluwalia et al.	11-02-2006
		2006-0251623	A1	Bachmann et al.	11-09-2006
		2006-0251677	A1	Bachmann et al.	11-09-2006
		2006-0286070	A1	Hartmann et al.	12-21-2006

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/690,495		ATTY. DOCKET NO.: C1039.70083US00	
				FILING DATE: October 21, 2003		CONFIRMATION NO.: 8657	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie	
Sheet	4	of	20				

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		EP	0 092 574	A1	Molecular Biosystems, Inc.	04-28-1983	
		EP	1 393 745	A1	Hybridon, Inc.	03-03-2004	
		WO	90/14822	A1	Northwestern University	12-13-1990	
		WO	95/24929	A2	Brown University Research Foundation	09-21-1995	
		WO	96/40162	A1	East Carolina University	12-19-1996	
		WO	97/03702	A1	Brown University Research Foundation	02-06-1997	
		WO	97/30731	A3	The Immune Response Corporation	08-28-1997	
		WO	98/11211	A2	Hybridon et al.	03-19-1998	
		WO	98/29557	A1	Biovector Therapeutics	07-09-1998	Y-Abstract
		WO	98/49288	A1	Hybridon Inc.	11-05-1998	
		WO	98/51278	A2	INEX Pharmaceuticals Corp.	11-19-1998	
		WO	98/52962	A1	Merck and Co., Inc.	11-26-1998	
		WO	98/55495	A2	Dynavax Technologies Corporation	12-10-1998	
		WO	99/30686	A1	INEX Pharmaceuticals Corporation	06-24-1999	
		WO	99/33493	A1	INEX Pharmaceuticals Corporation	07-08-1999	
		WO	99/43350	A1	IOMAI Corporation	09-02-1999	
		WO	99/52549	A1	SmithKline Beecham Biologicals S.A.	10-29-1999	
		WO	99/55743	A1	INEX Pharmaceuticals Corporation	11-04-1999	
		WO	99/58118	A2	CPG Immunopharmaceuticals GMBH	11-18-1999	
		WO	99/61056	A3	Loeb Health Research Institute at the Ottawa Hospital	12-02-1999	
		WO	00/03683	A2	INEX Pharmaceuticals Corporation	01-27-2000	
		WO	00/15256	A2	Pasteur Merieux Serums Et Vaccins [FR]	03-23-2000	Y-Abstract
		WO	00/45849	A2	Genzyme Corporation	08-10-2000	
		WO	00/46365	A1	Virginia Commonwealth University	08-10-2000	
		WO	00/54803	A2	Panacea Pharmaceuticals, LLC.	09-21-2000	
		WO	00/61151	A2	The Government of the United States of America	10-19-2000	
		WO	00/67787	A2	The Immune Response Corporation	11-16-2000	
		WO	00/75304	A1	Aventis Pasteur [FR]	12-14-2000	Y-Abstract
		WO	01/22972	A2	Coley Pharmaceuticals, GmbH	04-05-2001	
		WO	01/35991	A2	Dynavax Technologies Corporation	05-25-2001	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/690,495		ATTY. DOCKET NO.: C1039.70083US00			
				FILING DATE: October 21, 2003		CONFIRMATION NO.: 8657			
				APPLICANT: Krieg et al.					
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie			
Sheet	5	of	20						

		WO	01/45750	A1	Regents of the University of California	06-28-2001	
		WO	01/68143	A2	Dynavax Technologies Corporation	09-20-2001	
		WO	01/68144	A2	Dynavax Technologies Corporation	09-20-2001	
		WO	01/83503	A2	Hybridon, Inc	11-08-2001	
		WO	01/85751	A1	Reliable Pharmaceutical, Inc.	11-15-2001	
		WO	01/93902	A2	Biosynexus Incorporated	12-13-2001	
		WO	02/26757	A2	Hybridon, Inc.	04-04-2002	
		WO	02/28428	A2	Aventis Pasteur [FR]	04-11-2002	Y-Abstract
		WO	02/036767	A3	INEX Pharmaceuticals Corporation	05-10-2002	
		WO	03/000232	A2	Dynavax Technologies Corporation	01-03-2003	
		WO	03/002065	A2	Chiron Corporation	01-09-2003	
		WO	03/024481	A2	Cytos Biotechnology AG	03-27-2003	
		WO	03/026688	A1	Pharmaderm Laboratories, Ltd.	04-03-2003	
		WO	03/035836	A2	Hybridon, Inc.	05-01-2003	
		WO	03/057822	A3	Hybridon, Inc.	07-17-2003	
		WO	03/066649	A1	Biomira Inc.	08-14-2003	
		WO	03/094963	A2	INEX Pharmaceuticals Corp.	11-20-2003	
		WO	2004/041183	A2	The Regents of the University of California	05-21-2004	
		WO	2004/058159	A2	Dynavax Technologies Corp.	07-15-2004	
		WO	2005/001055	A2	Hybridon Inc.	01-06-2005	
		WO	2005/004907	A1	Cytos Biotechnology AG	01-20-2005	
		WO	2005/004910	A2	Intercell Ag	01-20-2005	
		WO	2005/023289	A1	Intellectual Property Consulting Incorporated	03-17-2005	Y-Abstract
		WO	2006/002038	A2	Hybridon, Inc.	01-05-2006	
		WO	2006/012896	A1	Universitaetsklinikum Schleswig-Holstein	02-09-2006	Y-Abstract
		WO	2006/015872	A1	Mologen Ag	02-16-2006	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		Press Release, Hybridon, Inc. Hybridon shows immunomodulatory activity of synthetic oligonucleotides. Cambridge, MA. May 7, 2001.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/690,495		ATTY. DOCKET NO.: C1039.70083US00	
				FILING DATE: October 21, 2003		CONFIRMATION NO.: 8657	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie	
Sheet	6	of	20				

	AGRAWAL et al., Novel immunomodulatory oligonucleotides prevent development of allergic airway inflammation and airway hyperresponsiveness in asthma. <i>Int Immunopharmacol.</i> 2004 Jan;4(1):127-38.	
	AGRAWAL et al., Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. <i>Proc Natl Acad Sci U S A.</i> 1991 Sep 1;88(17):7595-9.	
	AGRAWAL et al., Medicinal chemistry and therapeutic potential of CpG DNA. <i>Trends Mol Med.</i> 2002 Mar;8(3):114-21.	
	AGRAWAL et al., Pharmacokinetics of antisense oligonucleotides. <i>Clin Pharmacokinet.</i> 1995 Jan;28(1):7-16.	
	ALPAR et al., Potential of particulate carriers for the mucosal delivery of DNA vaccines. <i>Biochem Soc Trans.</i> 1997 May;25(2):337S.	
	ANITESCU et al., Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12. <i>J Interferon Cytokine Res.</i> 1997 Dec;17(12):781-8.	
	ASKEW et al., CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. <i>J Immunol.</i> 2000 Dec 15;165(12):6889-95.	
	BALLAS et al., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. <i>J Immunol.</i> 1996 Sep 1;157(5):1840-5.	
	BARAL et al., Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen. <i>Cancer Immunol Immunother.</i> 2003 May;52(5):317-27.	
	BAUER et al., DNA activates human immune cells through a CpG sequence-dependent manner. <i>Immunology.</i> 1999 Aug;97(4):699-705.	
	BAUER et al., Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. <i>Proc Natl Acad Sci U S A.</i> 2001 Jul 31;98(16):9237-42.	
	BIANCO et al., Cationic carbon nanotubes bind to CpG oligodeoxynucleotides and enhance their immunostimulatory properties. <i>J Am Chem Soc.</i> 2005 Jan 12;127(1):58-9.	
	BLAZAR et al., Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. <i>Blood.</i> 2001 Aug 15;98(4):1217-25.	
	BOGGS et al., Characterization and modulation of immune stimulation by modified oligonucleotides. <i>Antisense Nucleic Acid Drug Dev.</i> 1997 Oct;7(5):461-71.	
	BOWERSOCK et al., Evaluation of an orally administered vaccine, using hydrogels containing bacterial exotoxins of <i>Pasteurella haemolytica</i> , in cattle. <i>Am J Vet Res.</i> 1994 Apr;55(4):502-9.	
	BROIDE et al., DNA-Based immunization for asthma. <i>Int Arch Allergy Immunol.</i> 1999 Feb-Apr;118(2-4):453-6.	
	BRUNNER et al., Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. <i>J Immunol.</i> 2000 Dec 1;165(11):6278-86.	
	CARPENTIER et al., Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. <i>Clin Cancer Res.</i> 2000 Jun;6(6):2469-73.	
	CHACE et al., Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. <i>Clin Immunol Immunopathol.</i> 1997 Aug;84(2):185-93.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/690,495		ATTY. DOCKET NO.: C1039.70083US00	
				FILING DATE: October 21, 2003		CONFIRMATION NO.: 8657	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie	
Sheet	7	of	20				

	CHAN et al., CpG-A and CpG-B oligodeoxynucleotides differentially affect the cytokine profile, chemokine receptor expression and T-cell priming function of human plasmacytoid dendritic cells. Blood. 2002;100:50b. Abstract #3666.	
	CHANG et al., The effect of CpG-oligodeoxynucleotides with different backbone structures and 3' hexameric deoxyriboguanosine run conjugation on the treatment of asthma in mice. J Allergy Clin Immunol. 2004;113(2):S323. Abstract 1196.	
	CHATURVEDI et al., Stabilization of triple-stranded oligonucleotide complexes: use of probes containing alternating phosphodiester and stereo-uniform cationic phosphoramidate linkages. Nucleic Acids Res. 1996 Jun 15;24(12):2318-23.	
	CHEN et al., Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J Virol. 1998 Jul;72(7):5757-61.	
	CHOI et al., The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant. Vaccine. 2002 Mar 15;20(13-14):1733-40.	
	COHEN, Selective anti-gene therapy for cancer: principles and prospects. Tohoku J Exp Med. 1992 Oct;168(2):351-9.	
	COOPER et al., Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine. 2004 Aug 13;22(23-24):3136-43.	
	COWDERY et al., Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol. 1996 Jun 15;156(12):4570-5.	
	CROOKE et al., Phosphorothioate Oligonucleotides. Therapeut Apps. 1995;ch5:63-84.	
	CRYZ et al., European Commission COST/STD Initiative. Report of the expert panel VII. Vaccine delivery systems. Vaccine. 1996 May;14(7):665-90.	
	DAFTARIAN et al., Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. Cancer Res. 2004 Aug 1;64(15):5407-14.	
	DAHESHIA et al., Immune induction and modulation by topical ocular administration of plasmid DNA encoding antigens and cytokines. Vaccine. 1998 Jul;16(11-12):1103-10.	
	DALPKE et al., CpG-DNA as immune response modifier. Int J Med Microbiol. 2004 Oct;294(5):345-54.	
	DASS et al., Immunostimulatory activity of cationic-lipid-nucleic-acid complexes against cancer. J Cancer Res Clin Oncol. 2002 Apr;128(4):177-81. Abstract Only.	
	DAVILA et al., Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res. 2003 Jun 15;63(12):3281-8.	
	DAVIS, Use of CpG DNA for enhancing specific immune responses. Curr Top Microbiol Immunol. 2000;247:171-83.	
	DAVIS et al., CpG ODN is safe and highly effective in humans as adjuvant to HBV vaccine: Preliminary results of Phase I trial with CpG ODN 7909. Third Annual Conference on Vaccine Res. 2000. Abstract s25, number 47.	
	DELONG et al., Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. J Pharm Sci. 1997 Jun;86(6):762-4. Abstract Only.	
	ELDRIDGE et al., Biodegradable microspheres as a vaccine delivery system. Mol Immunol. 1991 Mar;28(3):287-94. Abstract Only.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/690,495		ATTY. DOCKET NO.: C1039.70083US00	
				FILING DATE: October 21, 2003		CONFIRMATION NO.: 8657	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie	
Sheet	8	of	20				

	EMI et al., Gene transfer mediated by polyarginine requires a formation of big carrier-complex of DNA aggregate. Biochem Biophys Res Commun. 1997 Feb 13;231(2):421-4.	
	FILION et al., Major limitations in the use of cationic liposomes for DNA delivery. Int J Pharmaceut. 1998; 162:159-70.	
	FRALEY et al., New generation liposomes: the engineering of an efficient vehicle for intracellular delivery of nucleic acids. Trends Biochem Sci. 1981;6:77-80.	
	GALLICHAN et al., Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine. 1995 Nov;13(16):1589-95.	
	GALLICHAN et al., Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol. 2001 Mar 1;166(5):3451-7.	
	GAO et al., Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-alpha through a post-transcriptional mechanism. J Immunol. 2001 Jun 1;166(11):6855-60.	
	GARBI et al., CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol. 2004 May 15;172(10):5861-9.	
	GAREGG et al., Nucleoside H-phosphonates. IV. Automated solid phase synthesis of oligoribonucleotides by the hydrogenphosphonate approach. Tetrahedron Lett. 1986; 27(34):4055-8.	
	GASTON et al., CpG methylation has differential effects on the binding of YY1 and ETS proteins to the bi-directional promoter of the Surf-1 and Surf-2 genes. Nucleic Acids Res. 1995 Mar 25;23(6):901-9.	
	GOODMAN et al., Selective modulation of elements of the immune system by low molecular weight nucleosides. J Pharmacol Exp Ther. 1995 Sep;274(3):1552-7.	
	GOUTTEFANGEAS et al., Problem solving for tumor immunotherapy. Nat Biotechnol. 2000 May;18(5):491-2.	
	GREGORIADIS et al., Liposomes for drugs and vaccines. Trends Biotechnol. 1985;3:235-41.	
	GREGORIADIS et al., Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 1995 Dec;13(12):527-37.	
	GROSSMANN et al., Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. J Immunother. 2001 May-Jun;24(3):237-41.	
	GURSEL et al., Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol. 2002 May;71(5):813-20. Abstract Only.	
	HADDEN et al., Immunostimulants. Trends Pharmacol Sci. 1993 May;14(5):169-74.	
	HAFNER et al., Antimetastatic effect of CpG DNA mediated by type I IFN. Cancer Res. 2001 Jul 15;61(14):5523-8.	
	HAHM et al., Efficacy of polyadenylic polyuridylic acid in the treatment of chronic active hepatitis B. Int J Immunopharmacol. 1994 Mar;16(3):217-25.	
	HALPERN et al., Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell Immunol. 1996 Jan 10;167(1):72-8.	
	HANEBERG et al., Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infect Immun. 1994 Jan;62(1):15-23.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/690,495		ATTY. DOCKET NO.: C1039.70083US00		
				FILING DATE: October 21, 2003		CONFIRMATION NO.: 8657		
				APPLICANT: Krieg et al.				
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie		
Sheet	9	of	20					

		HARRINGTON et al., Adjuvant effects of low doses of a nuclease-resistant derivative of polyinosinic acid . polycytidylic acid on antibody responses of monkeys to inactivated Venezuelan equine encephalomyelitis virus vaccine. Infect Immun. 1979 Apr;24(1):160-6.	
		HARTMANN et al., CpG DNA and LPS induce distinct patterns of activation in human monocytes. Gene Ther. 1999 May;6(5):893-903.	
		HARTMANN et al., Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 2000 Jan 15;164(2):944-53.	
		HARTMANN et al., Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes. J Pharmacol Exp Ther. 1998 May;285(2):920-8.	
		HARTMANN et al., Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol. 2000 Feb 1;164(3):1617-24.	
		HARTMANN et al., CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9305-10.	
		HAYNES et al., Particle-mediated nucleic acid immunization. J Biotechnol. 1996 Jan 26;44(1-3):37-42.	
		HECKELSMILLER et al., Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol. 2002 Oct 1;169(7):3892-9.	
		HEEG et al., CpG DNA as a Th1 trigger. Int Arch Allergy Immunol. 2000 Feb;121(2):87-97.	
		HENRY et al., Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J Pharmacol Exp Ther. 2000 Feb;292(2):468-79.	
		HOPKIN et al., Curbing the CpGs of Bacterial and Viral DNA. BioMedNet. 1999 Jun25; Issue 57.	
		HUANG et al., Induction and regulation of Th1-inducing cytokines by bacterial DNA, lipopolysaccharide, and heat-inactivated bacteria. Infect Immun. 1999 Dec;67(12):6257-63.	
		HUDSON et al., Nucleic acid dendrimers: Novel biopolymer structures. J Am Chem Soc. 1993;115:2119-24.	
		HUNTER et al., Biodegradable microspheres containing group B Streptococcus vaccine: immune response in mice. Am J Obstet Gynecol. 2001 Nov;185(5):1174-9.	
		IHO et al., Oligodeoxynucleotides containing palindrome sequences with internal 5'-CpG-3' act directly on human NK and activated T cells to induce IFN-gamma production in vitro. J Immunol. 1999 Oct 1;163(7):3642-52.	
		IOANNOU et al., The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol. 2002 Sep;76(18):9002-10.	
		IVERSEN et al., In vivo studies with phosphorothioate oligonucleotides: pharmacokinetics prologue. Anticancer Drug Des. 1991 Dec;6(6):531-8.	
		JAKOB et al., Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol. 1998 Sep 15;161(6):3042-9.	
		JAKOB et al., Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation of Th1 responses. Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):457-61.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/690,495		ATTY. DOCKET NO.: C1039.70083US00	
				FILING DATE: October 21, 2003		CONFIRMATION NO.: 8657	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie	
Sheet	10	of	20				

	JASCHKE et al., Automated incorporation of polyethylene glycol into synthetic oligonucleotides. Tetrahedron Lett. 1993;34(2):301-4.	
	JIANG et al., Enhancing immunogenicity by CpG DNA. Curr Opin Mol Ther. 2003 Apr;5(2):180-5.	
	JIAO et al., Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. J Gen Virol. 2004 Jun;85(Pt 6):1545-53.	
	JUFFERMANS et al., CpG oligodeoxynucleotides enhance host defense during murine tuberculosis. Infect Immun. 2002 Jan;70(1):147-52.	
	KANDIMALLA et al., A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif. Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14303-8. Epub 2003 Nov 10.	
	KANDIMALLA et al., Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships. Bioorg Med Chem. 2001 Mar;9(3):807-13.	
	KANDIMALLA et al., Towards optimal design of second-generation immunomodulatory oligonucleotides. Curr Opin Mol Ther. 2002 Apr;4(2):122-9.	
	KANDIMALLA et al., Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles. Nucleic Acids Res. 2003 May 1;31(9):2393-400.	
	KATAOKA et al., Immunotherapeutic potential in guinea-pig tumor model of deoxyribonucleic acid from Mycobacterium bovis BCG complexed with poly-L-lysine and carboxymethylcellulose. Jpn J Med Sci Biol. 1990 Oct;43(5):171-82.	
	KLINMAN et al., Immunotherapeutic applications of CpG-containing oligodeoxynucleotides. Drug News Perspect. 2000 Jun;13(5):289-96.	
	KLINMAN et al., Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004 Apr;4(4):249-58.	
	KLINMAN et al., Immune recognition of foreign DNA: a cure for bioterrorism? Immunity. 1999 Aug;11(2):123-9.	
	KLINMAN et al., Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol. 1997 Apr 15;158(8):3635-9.	
	KLINMAN et al., CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2879-83.	
	KOVARIK et al., CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol. 1999 Feb 1;162(3):1611-7.	
	KRANZER et al., CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12. Immunology. 2000 Feb;99(2):170-8.	
	KRIEG et al., Immune effects and therapeutic applications of CpG motifs in bacterial DNA. Immunopharmacology. 2000 Jul 25;48(3):303-5.	
	KRIEG et al., Lymphocyte activation mediated by oligodeoxynucleotides or DNA containing novel un-methylated CpG motifs. American College of Rheumatology 58 th National Scientific Meeting. Minneapolis, Minnesota, October 22, 1994. Abstracts. Arthritis Rheum. 1994 Sep;37(9 Suppl).	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/690,495		ATTY. DOCKET NO.: C1039.70083US00	
				FILING DATE: October 21, 2003		CONFIRMATION NO.: 8657	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie	
Sheet	11	of	20				

	KRIEG et al., Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res Dev. 1995 Winter;5(4):241.	
	KRIEG et al., Leukocyte stimulation by oligodeoxynucleotides, Applied Antisense Oligonucleotide Technology, 1998; 431-448.	
	KRIEG, CpG DNA: a pathogenic factor in systemic lupus erythematosus? J Clin Immunol. 1995 Nov;15(6):284-92.	
	KRIEG et al., Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy. Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):1048-52.	
	KRIEG et al., The role of CpG dinucleotides in DNA vaccines. Trends Microbiol. 1998 Jan;6(1):23-7.	
	KRIEG, An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. J Lab Clin Med. 1996 Aug;128(2):128-33.	
	KRIEG et al., Applications of immune stimulatory CpG DNA for antigen-specific and antigen-nonspecific cancer immunotherapy. Eur J Canc. 1999 Oct; 35/Suppl4:S10. Abstract #14.	
	KRIEG et al., CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002;20:709-60.	
	KRIEG et al., Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. Immunol Today. 2000 Oct;21(10):521-6.	
	KRIEG et al., Chapter 8: Immune Stimulation by Oligonucleotides. in Antisense Research and Application. Crooke, editor. 1998; 243-62.	
	KRIEG et al., P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides. Oligonucleotides. 2003;13(6):491-9.	
	KRIEG et al., Bacterial DNA or oligonucleotides containing CpG motifs protect mice from lethal L. monocytogenes challenge. 1996 Meeting on Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor Laboratory, September 9-13, 1996: 116.	
	KRIEG et al., Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther. 2001 Feb;3(1):15-24.	
	KRIEG et al., Chapter 7: CpG oligonucleotides as immune adjuvants. Ernst Schering Research Found Workshop 2001; 30:105-18.	
	KRIEG, Immune effects and mechanisms of action of CpG motifs. Vaccine. 2001 Nov 8;19(6):618-22.	
	KRIEG et al., Chapter 17: Immune stimulation by oligonucleotides. in Antisense Drug Tech. 2001;1394:471-515.	
	KRIEG et al., Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta. 1999 Dec 10;1489(1):107-16.	
	KRIEG et al., The CpG motif: Implications for clinical immunology. BioDrugs. 1998 Nov 1;10(5):341-6.	
	KRIEG, The role of CpG motifs in innate immunity. Curr Opin Immunol. 2000 Feb;12(1):35-43.	
	KRIEG et al., Mechanism of action of CpG DNA. Curr Top Microbiol Immunol. 2000;247:1-21.	
	KRIEG et al., Mechanisms and therapeutic applications of immune stimulatory CpG DNA. Pharmacol Ther. 1999 Nov;84(2):113-20.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/690,495		ATTY. DOCKET NO.: C1039.70083US00	
				FILING DATE: October 21, 2003		CONFIRMATION NO.: 8657	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie	
Sheet	12	of	20				

	KRIEG et al., Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. <i>Proc Natl Acad Sci U S A</i> . 1998 Oct 13;95(21):12631-6.	
	KRIEG et al., CpG DNA: a novel immunomodulator. <i>Trends Microbiol</i> . 1999 Feb;7(2):64-5.	
	KRIEG, Signal transduction induced by immunostimulatory CpG DNA. <i>Springer Semin Immunopathol</i> . 2000;22(1-2):97-105.	
	KRIEG et al., Infection. In McGraw Hill Book. 1996: 242-3.	
	KRIEG et al., Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. <i>Trends Microbiol</i> . 1996 Feb;4(2):73-6.	
	KRIEG, Therapeutic potential of Toll-like receptor 9 activation. <i>Nat Rev Drug Discov</i> . 2006 Jun;5(6):471-84.	
	KRIEG et al., Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. <i>J Immunother</i> . 2004 Nov-Dec;27(6):460-71.	
	KUKOWSKA-LATALLO et al., Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. <i>Proc Natl Acad Sci U S A</i> . 1996 May 14;93(10):4897-902.	
	KURAMOTO et al., Changes of host cell infiltration into Meth A fibrosarcoma tumor during the course of regression induced by injections of a BCG nucleic acid fraction. <i>Int J Immunopharmacol</i> . 1992 Jul;14(5):773-82.	
	KURAMOTO et al., In situ infiltration of natural killer-like cells induced by intradermal injection of the nucleic acid fraction from BCG. <i>Microbiol Immunol</i> . 1989;33(11):929-40.	
	LEE et al., Immuno-stimulatory effects of bacterial-derived plasmids depend on the nature of the antigen in intramuscular DNA inoculations. <i>Immunology</i> . 1998 Jul;94(3):285-9.	
	LETSINGER et al., Cholesteryl-conjugated oligonucleotides: synthesis, properties, and activity as inhibitors of replication of human immunodeficiency virus in cell culture. <i>Proc Natl Acad Sci U S A</i> . 1989 Sep;86(17):6553-6.	
	LETSINGER et al., Synthesis and properties of modified oligonucleotides. <i>Nucleic Acids Symp Ser</i> . 1991;(24):75-8.	
	LIPFORD et al., CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. <i>Eur J Immunol</i> . 1997 Sep;27(9):2340-4.	
	LIPFORD et al., Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. <i>Eur J Immunol</i> . 1997 Dec;27(12):3420-6.	
	LIPFORD et al., Bacterial DNA as immune cell activator. <i>Trends Microbiol</i> . 1998 Dec;6(12):496-500.	
	LIU et al., CpG ODN is an effective adjuvant in immunization with tumor antigen. <i>J Invest Med</i> . 1997 Sept;45(7):333A.	
	LONSDORF et al., Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. <i>J Immunol</i> . 2003 Oct 15;171(8):3941-6.	
	MACKELLAR et al., Synthesis and physical properties of anti-HIV antisense oligonucleotides bearing terminal lipophilic groups. <i>Nucleic Acids Res</i> . 1992 Jul 11;20(13):3411-7.	
	MAGNUSSON et al., Importance of CpG dinucleotides in activation of natural IFN-alpha-producing cells by a lupus-related oligodeoxynucleotide. <i>Scand J Immunol</i> . 2001 Dec;54(6):543-50.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/690,495		ATTY. DOCKET NO.: C1039.70083US00		
				FILING DATE: October 21, 2003		CONFIRMATION NO.: 8657		
				APPLICANT: Krieg et al.				
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie		
Sheet	13	of	20					

	MALLOY et al., Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS. Eur J Immunol. 1995 Oct;25(10):2835-41.	
	MARTIN-OROZCO et al., Enhancement of antigen-presenting cell surface molecules involved in cognate interactions by immunostimulatory DNA sequences. Int Immunol. 1999 Jul;11(7):1111-8.	
	McCLUSKIE et al., CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol. 1998 Nov 1;161(9):4463-6.	
	McCLUSKIE et al., CpG DNA as mucosal adjuvant. Vaccine. 2000; 18:231-237.	
	McCLUSKIE et al., Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine. 2001 Oct 15;19(4-5):413-22.	
	McCLUSKIE et al., CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine. 2001 Nov 22;19(7-8):950-7.	
	McCLUSKIE et al., Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol Med. 1999 May;5(5):287-300.	
	McCLUSKIE et al., The use of CpG DNA as a mucosal vaccine adjuvant. Curr Opin Investig Drugs. 2001 Jan;2(1):35-9.	
	McCLUSKIE et al., Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution. Mol Med. 2000 Oct;6(10):867-77.	
	McCLUSKIE et al., The role of CpG in DNA vaccines. Springer Semin Immunopathol. 2000;22(1-2):125-32.	
	McGHEE et al., The mucosal immune system: from fundamental concepts to vaccine development. Vaccine. 1992;10(2):75-88.	
	MICONNET et al., CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J Immunol. 2002 Feb 1;168(3):1212-8.	
	MILAS et al., CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res. 2004 Aug 1;64(15):5074-7.	
	MOJCIK et al., Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF env causes immune effects in vivo in a sequence-specific manner. Clin Immunol Immunopathol. 1993 May;67(2):130-6.	
	MUI et al., Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J Pharmacol Exp Ther. 2001 Sep;298(3):1185-92.	
	MUTWIRI et al., Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J Control Release. 2004 May 31;97(1):1-17.	
	NIELSEN et al., Peptide nucleic acid (PNA). A DNA mimic with a peptide backbone. Bioconjug Chem. 1994 Jan-Feb;5(1):3-7.	
	OKADA et al., Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer. 1998 Oct 5;78(2):196-201.	
	PAL et al., Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein by use of CpG oligodeoxynucleotides as an adjuvant induces a protective immune response against an intranasal chlamydial challenge. Infect Immun. 2002 Sep;70(9):4812-7.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/690,495		ATTY. DOCKET NO.: C1039.70083US00	
				FILING DATE: October 21, 2003		CONFIRMATION NO.: 8657	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie	
Sheet	14	of	20				

	PAVLICK et al., Novel therapeutic agents under investigation for malignant melanoma. Expert Opin Investig Drugs. 2003 Sep;12(9):1545-58.	
	PAYETTE et al., History of vaccines and positioning of current trends. Curr Drug Targets Infect Disord. 2001 Nov;1(3):241-7.	
	PISETSKY et al., The immunologic properties of DNA. J Immunol. 1996 Jan 15;156(2):421-3.	
	PISETSKY et al., Influence of backbone chemistry on immune activation by synthetic oligonucleotides. Biochem Pharmacol. 1999 Dec 15;58(12):1981-8.	
	PISETSKY, Immunologic consequences of nucleic acid therapy. Antisense Res Dev. 1995 Fall;5(3):219-25.	
	PISETSKY et al., Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides. Mol Biol Rep. 1993 Oct;18(3):217-21.	
	PISETSKY, The influence of base sequence on the immunostimulatory properties of DNA. Immunol Res. 1999;19(1):35-46.	
	PISETSKY et al., The influence of base sequence on the immunological properties of defined oligonucleotides. Immunopharmacology. 1998 Nov;40(3):199-208.	
	POLANCZYK et al., Immunostimulatory effects of DNA and CpG motifs. Cent Eur J of Immunol. 2000;25(3):160-6.	
	RAGHAVAN et al., Orally administered CpG oligodeoxynucleotide induces production of CXC and CC chemokines in the gastric mucosa and suppresses bacterial colonization in a mouse model of Helicobacter pylori infection. Infect Immun. 2003 Dec;71(12):7014-22.	
	RANKIN et al., CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev. 2001 Oct;11(5):333-40.	
	REDDY et al., Design of synthetic immunostimulatory motifs as agonists of Toll-like receptor 9: Use of N3-methyl-dC and N1-methyl-dG. 231 st ACS National Meeting. Atlanta, GA, United States. March 26-30, 2006. Meeting Abstract.	
	REITZ et al., Small-molecule immunostimulants. Synthesis and activity of 7,8-disubstituted guanosines and structurally related compounds. J Med Chem. 1994 Oct 14;37(21):3561-78.	
	REVAZ et al., The importance of mucosal immunity in defense against epithelial cancers. Curr Opin Immunol. 2005 Apr;17(2):175-9.	
	ROBERTSON et al., Crohn's trial shows the pros of antisense. Nat Biotechnol. 1997 Mar;15(3):209.	
	RODGERS et al., Effects of acute administration of O,S,S-trimethyl phosphorodithioate on the generation of cellular and humoral immune responses following in vitro stimulation. Toxicology. 1988 Oct;51(2-3):241-53.	
	ROMAN et al., Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med. 1997 Aug;3(8):849-54.	
	ROTHENFUSSER et al., Recent advances in immunostimulatory CpG oligonucleotides. Curr Opin Mol Ther. 2003 Apr;5(2):98-106.	
	SAJIC et al., Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge. J Med Virol. 2003 Dec;71(4):561-8.	
	SANDS et al., Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol. 1994 May;45(5):932-43.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/690,495		ATTY. DOCKET NO.: C1039.70083US00	
				FILING DATE: October 21, 2003		CONFIRMATION NO.: 8657	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie	
Sheet	15	of	20				

	SATOH et al., The study of mechanisms in CpG oligodeoxynucleotides-induced aggravation in murine allergic contact dermatitis to 2,4-dinitrofluorobenzene. Fukushima Igaku Zasshi. 2002;52(3):237-50. Abstract.	
	SCHMIDT et al., Cytokine and Ig-production by CG-containing sequences with phosphodiester backbone and dumbbell-shape. Allergy. 2006 Jan;61(1):56-63.	
	SCHWARTZ et al., Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. J Immunol. 1999 Jul 1;163(1):224-31.	
	SESTER et al., Phosphorothioate backbone modification modulates macrophage activation by CpG DNA. J Immunol. 2000 Oct 15;165(8):4165-73.	
	SHCHEPINOV et al., Oligonucleotide dendrimers: From poly-labelled DNA probes to stable nano-structures. Glen Research Glen Report located at < http://www.glenresearch.com/glenreports/GR12-11.html > visited on March 3, 2006. 7 pages.	
	SHCHEPINOV et al., Oligonucleotide dendrimers: stable nano-structures. Nucleic Acids Res. 1999 Aug 1;27(15):3035-41.	
	SINGH et al., Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA. Pharm Res. 2001 Oct;18(10):1476-9.	
	SJOLANDER et al., Kinetics, localization and isotype profile of antibody responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins. Scand J Immunol. 1996 Feb;43(2):164-72.	
	SONEHARA et al., Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon. J Interferon Cytokine Res. 1996 Oct;16(10):799-803.	
	SPARWASSER et al., Bacterial DNA causes septic shock. Nature. 1997 Mar 27;386(6623):336-7.	
	SPARWASSER et al., Immunostimulatory CpG-oligodeoxynucleotides cause extramedullary murine hemopoiesis. J Immunol. 1999 Feb 15;162(4):2368-74.	
	SPARWASSER et al., Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Eur J Immunol. 1997 Jul;27(7):1671-9.	
	STEIN et al., Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev. 1994 Summer;4(2):67-9.	
	STEIN et al., Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 1988 Apr 25;16(8):3209-21.	
	STEIN et al., Non-antisense effects of oligodeoxynucleotides. Antisense Technology. 1997; ch11: 241-64.	
	STIRCHAK et al., Uncharged stereoregular nucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages. Nucleic Acids Res. 1989 Aug 11;17(15):6129-41.	
	STUNZ et al., Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol. 2002 May;32(5):1212-22.	
	SUN et al. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med. 1998 Dec 21;188(12):2335-42.	
	SUN et al. Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons. Springer Semin Immunopathol. 2000;22(1-2):77-84.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/690,495		ATTY. DOCKET NO.: C1039.70083US00	
				FILING DATE: October 21, 2003		CONFIRMATION NO.: 8657	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie	
Sheet	16	of	20				

	TACKET et al., Phase I safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. <i>Vaccine</i> . 1999 Jul 16;17(22):2826-9.	
	TARKÖY et al., Nucleic-Acid Analogues with Constraint Conformational Flexibility in the Sugar-Phosphate Backbone ('Bicyclo-DNA'). Part 1. Preparation of (3S,5'R)-2'-Deoxy-3',5'-ethano- α -D-ribonucleosides ('Bicyclonucleosides'). <i>Helv Chim Acta</i> . 1993 Feb 10;76(1): 481-510.	
	THREADGILL et al., Mitogenic synthetic polynucleotides suppress the antibody response to a bacterial polysaccharide. <i>Vaccine</i> . 1998 Jan;16(1):76-82.	
	UHLMANN et al., Recent advances in the development of immunostimulatory oligonucleotides. <i>Curr Opin Drug Discov Devel</i> . 2003 Mar;6(2):204-17.	
	VANENDRIESCHE et al., Acyclic oligonucleotides: possibilities and limitations. <i>Tetrahedron</i> . 1993 Aug 13;49(33): 7223-38.	
	VERTHELYI et al., Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. <i>Clin Immunol</i> . 2003 Oct;109(1):64-71.	
	VERTHELYI et al., Human peripheral blood cells differentially recognize and respond to two distinct CPG motifs. <i>J Immunol</i> . 2001 Feb 15;166(4):2372-7.	
	VICARI et al., Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. <i>J Exp Med</i> . 2002 Aug 19;196(4):541-9.	
	VLASSOV et al., In Vivo pharmacokinetics of oligonucleotides following administration by different routes. CRC Press, Inc. Chapter 5. 1995: 71-83.	
	VOLLMER et al., Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. <i>Antisense Nucleic Acid Drug Dev</i> . 2002 Jun;12(3):165-75.	
	VOLLMER et al., Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. <i>Eur J Immunol</i> . 2004 Jan;34(1):251-62.	
	VOLLMER et al., Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). <i>Oligonucleotides</i> . 2004 Spring;14(1):23-31.	
	WAGNER, Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. <i>Curr Opin Microbiol</i> . 2002 Feb;5(1):62-9.	
	WAGNER et al., CpG motifs are efficient adjuvants for genetic vaccines to induce antigen-specific protective anti-tumor T cell responses. 2000;203:429. Abstract R46.	
	WANG et al., CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma. <i>World J Gastroenterol</i> . 2005 Feb 28;11(8):1220-4.	
	WEERATNA et al., CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. <i>FEMS Immunol Med Microbiol</i> . 2001 Dec;32(1):65-71.	
	WEERATNA et al., CpG DNA induces stronger immune responses with less toxicity than other adjuvants. <i>Vaccine</i> . 2000 Mar 6;18(17):1755-62.	
	WEINER et al., The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. <i>J Leukoc Biol</i> . 2000 Oct;68(4):455-63.	
	WEINER et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. <i>Proc Natl Acad Sci U S A</i> . 1997 Sep 30;94(20):10833-7.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/690,495		ATTY. DOCKET NO.: C1039.70083US00	
				FILING DATE: October 21, 2003		CONFIRMATION NO.: 8657	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie	
Sheet	17	of	20				

		WERNETTE et al., CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation. Vet Immunol Immunopathol. 2002 Jan 15;84(3-4):223-36.	
		WHITESSELL et al., Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4665-9.	
		YI et al. Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J Immunol. 1998 Nov 1;161(9):4493-7.	
		YI et al., Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J Immunol. 1996 Dec 15;157(12):5394-402.	
		YI et al., IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J Immunol. 1996 Jan 15;156(2):558-64.	
		YI et al. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol. 1998 Jun 15;160(12):5898-906.	
		YU et al., Accessible 5'-end of CpG-containing phosphorothioate oligodeoxynucleotides is essential for immunostimulatory activity. Bioorg Med Chem Lett. 2000 Dec 4;10(23):2585-8.	
		YU et al., Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases. Bioorg Med Chem Lett. 2001 Sep 3;11(17):2263-7.	
		ZHAO et al., Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):495-502.	
		ZHAO et al., Modulation of oligonucleotide-induced immune stimulation by cyclodextrin analogs. Biochem Pharmacol. 1996 Nov 22;52(10):1537-44.	
		ZHAO et al., Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol. 1996 Jan 26;51(2):173-82.	
		ZHAO et al., Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity. Bioorg Med Chem Lett. 1999 Dec 20;9(24):3453-8.	
		ZHAO et al., Immunostimulatory activity of CpG containing phosphorothioate oligodeoxynucleotide is modulated by modification of a single deoxynucleoside. Bioorg Med Chem Lett. 2000 May 15; 10(10):1051-4. Abstract Only.	
		ZHU et al., Modulation of ovalbumin-induced Th2 responses by second-generation immunomodulatory oligonucleotides in mice. Int Immunopharmacol. 2004 Jul;4(7):851-62.	
		Patent Interference No. 105,171. Iowa Preliminary Motion 3 (for judgment based on failure to comply with 35 U.S.C. 135(b)). (Electronically filed, unsigned). June 7, 2004.	
		Patent Interference No. 105,171. Iowa Preliminary Motion 4 (for judgment of no interference in fact). (Electronically filed, unsigned). June 7, 2004.	
		Patent Interference No. 105,171. Iowa Preliminary Motion 5 (for judgment based on lack of enablement). (Electronically filed, unsigned). June 7, 2004.	
		Patent Interference No. 105,171. Iowa Preliminary Motion 6 (for judgment based on lack of adequate written description). (Electronically filed, unsigned). June 7, 2004.	
		Patent Interference No. 105,171. Iowa Preliminary Motion 7 (motion to redefine interference to designate claims as not corresponding to the Count). (Electronically filed, unsigned). June 7, 2004.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/690,495		ATTY. DOCKET NO.: C1039.70083US00	
				FILING DATE: October 21, 2003		CONFIRMATION NO.: 8657	
				APPLICANT: Krieg et al.			
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie	
Sheet	18	of	20				

	Patent Interference No. 105,171. Iowa Preliminary Motion 8 (contingent motion to redefine the Count). (Electronically filed, unsigned). June 7, 2004.	
	Patent Interference No. 105,171. Iowa Preliminary Motion 9 (motion for benefit of earlier application). (Electronically filed, unsigned). June 7, 2004.	
	Patent Interference No. 105,171. Iowa Preliminary Motion 10 (contingent motion to redefine the interference by adding a continuation application). (Electronically filed, unsigned). July 2, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 3 (to Iowa Preliminary Motion 3 for judgment under 35 USC 135(b)). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 4 (to Iowa Preliminary Motion 4 for judgment of no interference in fact). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 5 (to Iowa Preliminary Motion 5 for judgment that UC's claim is not enabled). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 6 (to Iowa Preliminary Motion 6 for judgment based on lack of adequate written description). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 7 (to Iowa Preliminary Motion 7 to redefine the interference). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 8 (to Iowa Preliminary Motion 8 to redefine the Count). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Response 9 (to Iowa Contingent Motion 9 for benefit). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 10 (to Iowa Contingent Motion 10 to redefine the interference). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 11 (to Iowa Contingent Motion 11 to suppress). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 3 (in support of Iowa Preliminary Motion 3 for judgment under 35 U.S.C. §135(b)) (Electronically filed, unsigned). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 4 (in support of Iowa Preliminary Motion for judgment of no interference in fact) (Electronically filed, unsigned). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 5 (in support of Iowa Preliminary Motion 5 for judgment that UC's claim 205 is not enabled) (Electronically filed, unsigned). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 6 (in support of Iowa Preliminary Motion 6 for judgment based on lack of adequate written description) (Electronically filed, unsigned). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 7 (in support of Iowa Preliminary Motion 7 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 8 (in support of Iowa Preliminary Motion 8 to redefine the count) (Electronically filed, unsigned). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 10 (in support of Iowa Preliminary Motion 10 to redefine the interference) (Electronically filed, unsigned). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 11 (in support of Iowa Miscellaneous Motion to suppress). (Electronically filed, unsigned). October 18, 2004.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/690,495		ATTY. DOCKET NO.: C1039.70083US00		
				FILING DATE: October 21, 2003		CONFIRMATION NO.: 8657		
				APPLICANT: Krieg et al.				
				GROUP ART UNIT: 1645		EXAMINER: Nina Archie		
Sheet	19	of	20					

		Patent Interference No. 105,171. Regents of the University of California Preliminary Statement. June 7, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 1 (to designate additional claims of Iowa patent as corresponding to the Count). June 7, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 2 (for judgment based on lack of written description support and introducing new matter). June 7, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 3 (for judgment based on anticipation). June 7, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 4 (for judgment based on obviousness). June 7, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 5 (for judgment based on anticipation). June 7, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 6 (for judgment based on inequitable conduct). June 7, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 7 (for benefit of an earlier application under 37 CFR 1.633(j)). July 2, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary Motion 8 (to add additional claims under 37 CFR 1.633(c)(2) and (i)). July 2, 2004.	
		Amended Claims for Application Number 09/265,191, filed March 10, 1999.	
		Patent Interference No. 105,171. Iowa Opposition 1 (opposition to motion to designate additional claims as corresponding to the Count) (Electronically filed, unsigned). September 9, 2004.	
		Patent Interference No. 105,171. Iowa Opposition 2 (opposition to motion for judgment based on lack of written description support and introducing new matter) (Electronically filed, unsigned). September 9, 2004.	
		Patent Interference No. 105,171. Iowa Opposition 3 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.	
		Patent Interference No. 105,171. Iowa Opposition 4 (opposition to motion for judgment based on obviousness) (Electronically filed, unsigned). September 9, 2004.	
		Patent Interference No. 105,171. Iowa Opposition 5 (opposition to motion for judgment based on anticipation) (Electronically filed, unsigned). September 9, 2004.	
		Patent Interference No. 105,171. Iowa Opposition 6 (opposition to motion for judgment based on inequitable conduct) (Electronically filed, unsigned). September 9, 2004.	
		Patent Interference No. 105,171. Iowa Opposition 7 (opposition to motion for benefit of an earlier application under 7 CFR 1.633(j)) (Electronically filed, unsigned). September 9, 2004.	
		Patent Interference No. 105,171. Iowa Opposition 8 (opposition to motion to add additional claims under 37 CFR 1.633 (2) and (i)) (Electronically filed, unsigned). September 9, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Reply 1 (to Iowa's opposition to UC's motion to designate Iowa claims as corresponding to the Count). October 15, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Reply 2 (to Iowa's opposition to UC Preliminary Motion 2 for Judgment). October 15, 2004.	
		Patent Interference No. 105,171. Regents of the University of California Reply 3 (to Iowa's Opposition to UC Preliminary Motion 3 for Judgment). October 15, 2004.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/690,495	ATTY. DOCKET NO.: C1039.70083US00
				FILING DATE: October 21, 2003	CONFIRMATION NO.: 8657
				APPLICANT: Krieg et al.	
				GROUP ART UNIT: 1645	EXAMINER: Nina Archie
Sheet	20	of	20		

	Patent Interference No. 105,171. Regents of the University of California Reply 4 (to Iowa's Opposition to UC Preliminary Motion 4 for Judgment). October 15, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Reply 5 (to Iowa's Opposition to UC Preliminary Motion 5 for Judgment). October 15, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Reply 6 (to Iowa's opposition to UC Preliminary Motion 6 for judgment). October 15, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Reply 7 (to Iowa's Opposition to UC Preliminary Motion 7 for Benefit). October 15, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Reply 8 (to Iowa's Opposition to UC Preliminary Motion 8 to add additional claims). October 15, 2004.	
	Patent Interference No. 105,171. Decision on Motion under 37 CFR §41.125. March 10, 2005.	
	Patent Interference No. 105,171. Judgment and Order. March 10, 2005.	
	Patent Interference No. 105,171. Regents of the University of California. Brief of Appellant. July 5, 2005.	
	Patent Interference No. 105,171. University of Iowa and Coley Pharmaceutical Group, Inc. Brief of Appellees. August 17, 2005.	
	Patent Interference No. 105,171. Regents of the University of California. Reply Brief of Appellant. September 6, 2005.	
	Patent Interference No. 105,171. Regents of the University of California. Decision of CAFC. July 17, 2006.	

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.